Naples conference on Oncology. Naples ITA, 1995/09/27.
To be cost-effective, PET must be diagnostically accurate and effective in improving management without increasing treatment cost.
To evaluate diagnostic accuracy, we performed prospective evaluations of whole-body PET imaging in staging of non-small-cell lung cancer (99 patients), detection of recurrent colorectal cancer (57 patients), diagnosis of metastatic melanoma (36 patients), and staging of advanced head and neck cancer (29 patients).
In each case, PET was more accurate than anatomic imaging for determination of the presence and extent of tumor and demonstration of nonresectable disease.
PET was also more accurate than conventional imaging in staging Hodgkin's disease (30 patients).
We evaluated the management impact of PET retrospectively, by reviewing the treatment records of 72 patients with solitary pulmonary nodules or non-small-cell lung cancer, 68 patients with known or suspected recurrent colorectal cancer, 45 patients with known or suspected metastatic melanoma, and 29 patients with advanced head and neck tumors.
PET improved patient management by avoiding surgery for nonresectable tumor and for CT abnormalities that proved to be benign by PET imaging.
For determining cost impact, the costs of surgical procedures were determined from Medicare reimbursement rates, and the cost of a PET study was taken to be $1800. (...)
Mots-clés Pascal : Tomoscintigraphie, Positon, Corps entier, Tumeur maligne, Exploration, Analyse coût efficacité, Classification par stade, Economie santé, Etats Unis, Amérique du Nord, Amérique, Homme, Exploration radioisotopique, Imagerie médicale
Mots-clés Pascal anglais : Emission tomography, Positron, Whole body, Malignant tumor, Exploration, Cost efficiency analysis, Staging, Health economy, United States, North America, America, Human, Radionuclide study, Medical imagery
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0501219
Code Inist : 002B24B11. Création : 10/04/1997.